Johnson & Johnson Announces Breakthrough Results: Nipocalimab SLE Phase 2 Study Demonstrates Significant Reduction in Systemic Lupus Erythematosus Activity
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
Novo Nordisk Launches Wegovy Pill in the UAE
Novo Nordisk has expanded global access to obesity care by launching the once-daily Wegovy pill in the United Arab Emirates, offering a non-injectable alternative with a 17% mean weight loss and MACE risk reduction.
AstraZeneca Camizestrant Breast Cancer Treatment Delays Disease Progression by 55%
The Phase III SERENA-6 trial reveals that switching to AstraZeneca Camizestrant Breast Cancer Treatment yields a 55% reduction in disease progression risk for advanced HR-positive breast cancer patients with emergent ESR1 mutations.
FDA Accepts Priority Review for Roche Giredestrant in Early-Stage Breast Cancer
Roche announces FDA Priority Review for giredestrant, the first oral SERD showing positive phase III results in the curative, adjuvant setting for ER-positive early breast cancer.
Roche Obesity Portfolio Forges Ahead as Enicepatide and Petrelintide Show Landmark Phase II Efficacy
Roche announces groundbreaking Phase II data for enicepatide and petrelintide ahead of the ADA 2026 Scientific Sessions, positioning its pipeline for best-in-class weight loss and advanced combination therapies.
New 144-Week Data Affirms Superiority of Novartis Scemblix CML Treatment
Novartis announced impressive 144-week data for its groundbreaking STAMP inhibitor, showcasing widening superior molecular response rates and better tolerability compared to standard TKIs in newly diagnosed CML patients.
Pfizer Talzenna Xtandi Prostate Cancer Trial Results Demonstrate Over 50% Reduction in Disease Progression Risk
Pfizer’s Phase 3 TALAPRO-3 trial reveals that combining Talzenna with Xtandi significantly improves radiographic progression-free survival by more than 50% in HRR gene-mutated mCSPC patients.
Johnson & Johnson Presents Historic Survival Metrics with Rybrevant for Atypical EGFR-mutated NSCLC
Updated data from the CHRYSALIS-2 study reveals that Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® combination achieves a historic median overall survival of 41.0 months as a first-line therapy for atypical EGFR-mutated advanced non-small cell lung cancer.
Johnson & Johnson Reports Tecvayli Multiple Myeloma Treatment Outperforms Standard Care in Phase 3 Trial
Johnson & Johnson has announced groundbreaking Phase 3 results for Tecvayli Multiple Myeloma Treatment, demonstrating its superiority over standard-of-care therapies in improving overall survival as early as the first relapse.
Pfizer LORBRENA CROWN Trial: Record 7-Year Survival Data in NSCLC
Landmark seven-year results from Pfizer’s CROWN study show LORBRENA (lorlatinib) reduces the risk of disease progression or death by 81% in ALK+ NSCLC, setting a new standard for oncology care.